Beta Bionics CCO sells 275 shares under 10b5-1 plan
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 275 shares of Common Stock at $12.31 per share. After this transaction, he directly holds 130,612 shares. The sale was executed under a pre-arranged Rule 10b5-1 Plan adopted on May 13, 2025, indicating it was scheduled in advance.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 275 | $12.31 | $3K |
Footnotes (1)
- F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.
Key Figures
Key Terms
Rule 10b5-1 Plan regulatory
open-market sale financial
Common Stock financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Beta Bionics (BBNX) executive Mark Hopman report in this Form 4?
Was the Beta Bionics (BBNX) insider sale made under a Rule 10b5-1 plan?
What role does Mark Hopman hold at Beta Bionics (BBNX)?
Does this Beta Bionics (BBNX) Form 4 include any option exercises or derivative transactions?
AI-generated analysis. How Rhea-AI works. Not financial advice.